Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BAFF serum levels in myasthenia gravis: effects of therapy.

Literature DB >> 21559937

BAFF serum levels in myasthenia gravis: effects of therapy.

Flavia Scuderi, Paolo E Alboini, Emanuela Bartoccioni, Amelia Evoli.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2011 PMID： 21559937 DOI： 10.1007/s00415-011-6092-z

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

× No keyword cloud information.

10 in total

Review 1. Myasthenia gravis.

Authors: A Vincent; J Palace; D Hilton-Jones
Journal: Lancet Date: 2001-06-30 Impact factor: 79.321

2. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity.

Authors: Fabienne Mackay; Charles R Mackay
Journal: Trends Immunol Date: 2002-03 Impact factor: 16.687

3. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis.

Authors: Mathula Thangarajh; Thomas Masterman; Lars Helgeland; Uros Rot; Malin V Jonsson; Geir Egil Eide; Ritva Pirskanen; Jan Hillert; Roland Jonsson
Journal: J Neuroimmunol Date: 2006-07-03 Impact factor: 3.478

Review 4. The kaleidoscope of glucorticoid effects on immune system.

Authors: Margherita Zen; Mariagrazia Canova; Carla Campana; Silvano Bettio; Linda Nalotto; Mariaelisa Rampudda; Roberta Ramonda; Luca Iaccarino; Andrea Doria
Journal: Autoimmun Rev Date: 2011-01-09 Impact factor: 9.754

5. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.

Authors: Florian Emmerich; Gürkan Bal; Alaa Barakat; Julian Milz; Caroline Mühle; Lorena Martinez-Gamboa; Thomas Dörner; Abdulgabar Salama
Journal: Br J Haematol Date: 2006-11-30 Impact factor: 6.998

6. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.

Authors: A Becker-Merok; C Nikolaisen; H C Nossent
Journal: Lupus Date: 2006 Impact factor: 2.911

7. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis.

Authors: Samia Ragheb; Robert Lisak; Richard Lewis; Gregory Van Stavern; Felicitas Gonzales; Kirk Simon
Journal: Arch Neurol Date: 2008-10

8. Serum BAFF expression in patients with myasthenia gravis.

Authors: Jee Young Kim; Young Yang; Joon-Shik Moon; Eun Young Lee; Sun Hwha So; Hong-Soo Lee; Kee Duk Park; Young-Chul Choi
Journal: J Neuroimmunol Date: 2008-06-30 Impact factor: 3.478

Review 9. BAFF: a local and systemic target in autoimmune diseases.

Authors: I Moisini; A Davidson
Journal: Clin Exp Immunol Date: 2009-07-30 Impact factor: 4.330

10. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors: P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal: J Exp Med Date: 1999-06-07 Impact factor: 14.307

10 in total

9 in total

1. Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

Authors: Muriel Sudres; Marie Maurer; Marieke Robinet; Jacky Bismuth; Frédérique Truffault; Diane Girard; Nadine Dragin; Mohamed Attia; Elie Fadel; Nicola Santelmo; Camille Sicsic; Talma Brenner; Sonia Berrih-Aknin
Journal: JCI Insight Date: 2017-04-06

2. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.

Authors: Y-Z Wang; F-F Tian; M Yan; J-M Zhang; Q Liu; J-Y Lu; W-B Zhou; H Yang; J Li
Journal: Clin Exp Immunol Date: 2014-05 Impact factor: 4.330

BAFF serum levels in myasthenia gravis: effects of therapy.

Review 1. Myasthenia gravis.

2. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity.

3. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis.

Review 4. The kaleidoscope of glucorticoid effects on immune system.

5. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.

6. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.

7. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis.

8. Serum BAFF expression in patients with myasthenia gravis.

Review 9. BAFF: a local and systemic target in autoimmune diseases.

10. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

1. Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

2. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.

3. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients.

4. Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis.

5. B-cell-activating factor and autoimmune myasthenia gravis.

6. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

7. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.

Review 8. New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.

9. Lower BAFF Levels in Myasthenic Patients Treated with Glucocorticoids.